Advancements in nanoengineered paclitaxel formulations: A comprehensive review of blood-brain barrier infiltration strategies for glioblastoma therapy

Biomedical engineering advances Pub Date : 2024-04-09 DOI:10.1016/j.bea.2024.100122

Stabak Das , Prithviraj Chakraborty , Debarupa Dutta Chakraborty , Lila Kanta Nath

{"title":"Advancements in nanoengineered paclitaxel formulations: A comprehensive review of blood-brain barrier infiltration strategies for glioblastoma therapy","authors":"Stabak Das , Prithviraj Chakraborty , Debarupa Dutta Chakraborty , Lila Kanta Nath","doi":"10.1016/j.bea.2024.100122","DOIUrl":null,"url":null,"abstract":"<div><p>Glioblastoma multiform (GBM), the most occurring brain tumor comprises radiation therapy, chemotherapy, and surgery as its treatment modalities. A significant hurdle is the insufficient or impeded transport of drugs to the central nervous system (CNS), linked to the protective influence of the blood-brain barrier (BBB). Nanotechnology can help to deliver therapeutic drugs into the central nervous system (CNS) by crossing the BBB. Paclitaxel (PTX) is a broad-spectrum anticancer compound that possesses scientifically proven anticancer activity. Despite having limited applications due to partial solubility and toxicity due to cosolvent preparation, it has shown encouraging outcomes in the treatment of GBM. In these cases, nanotechnology and nanoparticles added certain advantages such as increasing drug half-life, lowering toxicity, and enhancing the permeability and retention across BBB in tumor targeting. This review article is aimed at summarizing the current state of research works on nanotechnology and nanoparticles (NPs) containing PTX in the treatment of Glioblastoma.</p></div>","PeriodicalId":72384,"journal":{"name":"Biomedical engineering advances","volume":"7 ","pages":"Article 100122"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667099224000112/pdfft?md5=814c8467bd5ceca6ef71177d92eef918&pid=1-s2.0-S2667099224000112-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical engineering advances","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667099224000112","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Glioblastoma multiform (GBM), the most occurring brain tumor comprises radiation therapy, chemotherapy, and surgery as its treatment modalities. A significant hurdle is the insufficient or impeded transport of drugs to the central nervous system (CNS), linked to the protective influence of the blood-brain barrier (BBB). Nanotechnology can help to deliver therapeutic drugs into the central nervous system (CNS) by crossing the BBB. Paclitaxel (PTX) is a broad-spectrum anticancer compound that possesses scientifically proven anticancer activity. Despite having limited applications due to partial solubility and toxicity due to cosolvent preparation, it has shown encouraging outcomes in the treatment of GBM. In these cases, nanotechnology and nanoparticles added certain advantages such as increasing drug half-life, lowering toxicity, and enhancing the permeability and retention across BBB in tumor targeting. This review article is aimed at summarizing the current state of research works on nanotechnology and nanoparticles (NPs) containing PTX in the treatment of Glioblastoma.

Abstract Image

查看原文本刊更多论文

纳米工程紫杉醇制剂的进展：胶质母细胞瘤治疗的血脑屏障渗透策略综述

多形性胶质母细胞瘤（GBM）是发病率最高的脑肿瘤，其治疗方法包括放疗、化疗和手术。一个重要的障碍是药物向中枢神经系统（CNS）的传输不足或受阻，这与血脑屏障（BBB）的保护作用有关。纳米技术可以帮助穿过血脑屏障将治疗药物输送到中枢神经系统（CNS）。紫杉醇（PTX）是一种广谱抗癌化合物，具有科学证明的抗癌活性。尽管由于共溶剂制备造成的部分溶解性和毒性而导致其应用有限，但它在治疗 GBM 方面取得了令人鼓舞的成果。在这些情况下，纳米技术和纳米颗粒增加了一些优势，如增加药物半衰期、降低毒性、提高肿瘤靶向药物在 BBB 中的渗透性和滞留性。这篇综述文章旨在总结含有 PTX 的纳米技术和纳米颗粒（NPs）在治疗胶质母细胞瘤方面的研究现状。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomedical engineering advances Bioengineering, Biomedical Engineering

自引率

0.00%

发文量

审稿时长

59 days